Amphista Therapeutics announces first patient dosed in AMX-883 Phase 1 clinical trial for acute myeloid leukemia

The Medical News ·
Health & Medicine United Kingdom

Amphista Therapeutics Limited ('Amphista'), a leader in the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced dosing of the first patient in a Phase 1 trial for its lead candidate, AMX-883. Initiated following authorization from the U.S. Food and Drug Administration in June 2026, the BRAMLIE trial will investigate the safety,…

Read original article on The Medical News →

Related news